CMB 0.00% 0.4¢ cambium bio limited

Ann: Kyocera completes Progenza Due Diligence, page-12

  1. 433 Posts.
    lightbulb Created with Sketch. 232
    As TILLI has said, you make a good point bioqld about Kyocera not proceeding past DD if there were issues with Progenza.

    The question now is whether RGS' very weak financial position will force it to grant an exclusive licence to Kyocera for Progenza in Japan at a rock bottom price.

    I guess we should know soon enough, and I must admit things are looking somewhat brighter than they were just a few months ago. So, while my holding is a bit lighter than it was in February, today's announcement has moved my sentiment from Sell to Hold, for the time being.

    zeno9
 
watchlist Created with Sketch. Add CMB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.